Australia, Aug. 19 -- Envision Sciences Pty. Ltd., owns the trademark (2512568) for 'METIRRA' till Jan. 9, 2035.

Status: registered: Registered/protected

Classes: 1 [Chemical products for laboratory use (other than for medical or veterinary use); chemical preparations for use in the manufacture of pharmaceuticals and medicine; Diagnostic biomarkers for analytical, research and scientific use; chemicals for use in biotherapeutics, biosimilars and therapeutics product development and manufacturing processes; biochemicals, namely, proteins and polypeptides for use in the manufacture of pharmaceuticals for treating cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; reagents for testing sterility of pharmaceuticals; precursors for pharmaceuticals and medicines; stem cells for scientific or research purposes; cultures (other than for medical or veterinary use); immunological antibodies, other than for medical use; immunological antisera, other than for medical use; imaging materials; DNA, genetic and other biological and diagnostic materials (non-medical or veterinary), for use in chips, arrays and sensors; diagnostic biomarkers for in vitro testing for scientific use; diagnostic biomarkers for use in assessment of genomic analysis for scientific use; diagnostic biomarkers for use in assessment of chemical skin sensitizers for scientific use; diagnostic biomarkers for use in assessment of toxicological property of chemical compounds and mixtures for scientific use; diagnostic biomarkers for use in assessment of chemical respiratory sensitizers for scientific use; genetic identity tests comprised of reagents for use in science; biological preparations for use as assay samples for research use], 5 [Medicines; Medical preparations for the treatment of cancer; pharmaceutical and veterinary preparations and substances; biological preparations and substances for medical use; diagnostic biomarker reagents for medical purposes; diagnostic biomarkers for in vitro testing for medical use; diagnostic biomarkers for use in assessment of genomic analysis for medical use; diagnostic biomarkers for use in assessment of chemical skin sensitizers for medical use; diagnostic biomarkers for use in assessment of toxicological property of chemical compounds and mixtures for medical use; biopharmaceuticals for the treatment of cancer; biotechnological preparations for medical purposes; biotechnological preparations for medical use; biocides; diagnostic biomarkers for use in assessment of chemical respiratory sensitizers for medical use; diagnostic reagents and assays for detecting antigens for medical purposes; biotherapeutics; biosimilars; immunotherapeutic agents for cancer], 42 [Scientific research; Design of instruments; research and design services; scientific research services; laboratory analysis and research services; laboratory testing services; industrial analysis and research services; product design and process engineering for scientific and related purposes; project management services in the field of scientific research, analysis and related fields; scientific research for medical purposes in the field of cancerous diseases; medical research laboratories; laboratory analysis of materials; services relating to commercialisation of technologies and scientific discoveries; provision of facilities for scientific research and related business activities; information, advisory and consultancy services in relation to the aforementioned] and 44 [Diagnosis of diseases; medical analysis for the diagnosis and treatment of persons; disease diagnosis services; medical analysis services for the diagnosis and treatment of persons; medical analysis services for cancer diagnosis and prognosis; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical services; healthcare consultancy services [medical services]; medical consultancy services; provision of information in the field of cancer prevention, screening, diagnosis and treatment; RNA or DNA analysis for cancer diagnosis and prognosis; pathology services; oncology (medical services); services for the preparation of medical reports; information, advisory and consultancy services in relation to the aforementioned]

Type of Mark: Word

Date of Acceptance: Jan. 13

Registration Advertised: Aug. 18

For further details contact FB Rice Pty. Ltd. .

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2512568.

Disclaimer: Curated by HT Syndication.